Walgreens Boots Alliance (WBA) Opioid Dispensing and False Claims Case

• $WBA investors filed a lawsuit against Walgreens Boots Alliance, alleging the company misled shareholders about its compliance with federal regulations on opioid dispensing and reimbursement claims.

• On January 17, 2025, the Department of Justice (DOJ) filed a civil complaint accusing Walgreens of filling millions of unlawful opioid prescriptions and submitting false claims for reimbursement. Following this news, $WBA stock dropped 12.06%.

• $WBA investors can join this case to be notified about potential recovery.

Case Details:

Between April 2, 2020, and January 16, 2025, Walgreens repeatedly assured investors that it was committed to regulatory compliance, emphasizing its efforts to prevent opioid abuse and ensure proper pharmacy practices. The company stated that it had strong controls in place to monitor prescriptions and avoid improper claims under federal healthcare programs.

However, on January 17, 2025, the DOJ filed a lawsuit against Walgreens, alleging that since August 2012, the company knowingly filled millions of opioid prescriptions that lacked a legitimate medical purpose. The DOJ further claimed that Walgreens ignored red flags, pressured pharmacists to approve questionable prescriptions, and failed to implement proper compliance measures.

Following the DOJ’s announcement, Walgreens’ stock declined 12.06% over two trading days.

Based on these events, $WBA investors filed a lawsuit against Walgreens Boots Alliance, claiming the company:

• It misled investors about its opioid dispensing practices and regulatory compliance.

• It failed to disclose the legal risks tied to improper prescriptions and false reimbursement claims.

Investors believe Walgreens misrepresented its compliance efforts.